Identification of structural determinants of ligand selectivity in 5-HT₂ receptor subtypes on the basis of protein-ligand interactions.
暂无分享,去创建一个
Yong Seo Cho | Ae Nim Pae | Y. Cho | A. Pae | A. Cho | Jae Wan Jang | Art E Cho | Min Sup Kim | Min sup Kim
[1] M. Isaac. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. , 2005, Current topics in medicinal chemistry.
[2] J. Thompson,et al. Using CLUSTAL for multiple sequence alignments. , 1996, Methods in enzymology.
[3] Gebhard F. X. Schertler,et al. Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.
[4] Ruben Abagyan,et al. Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..
[5] Brian M. Smith,et al. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. , 2008, Journal of medicinal chemistry.
[6] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[7] B. Roth. Multiple serotonin receptors: clinical and experimental aspects. , 1994, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[8] G. Kennett,et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT2A, 5-HT2B and 5-HT2C receptors , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[9] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[10] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[11] B. Roth,et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.
[12] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[13] B. Kobilka,et al. New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.
[14] P. Delgado,et al. Hallucinogens, serotonin and obsessive-compulsive disorder. , 1998, Journal of psychoactive drugs.
[15] D. Middlemiss,et al. Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.
[16] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[17] W. L. Jorgensen,et al. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .
[18] M. Dallman,et al. Compulsive behavior in the 5-HT2C receptor knockout mouse , 2003, Physiology & Behavior.
[19] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[20] G. Kennett,et al. Indoline derivatives as 5-HT(2C) receptor agonists. , 2004, Bioorganic & medicinal chemistry letters.
[21] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[22] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[23] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[24] Marta Filizola,et al. Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.
[25] T. Blundell,et al. Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.
[26] B. Roth,et al. The expanded biology of serotonin. , 2009, Annual review of medicine.
[27] I. Lucki,et al. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. , 1989, The Journal of pharmacology and experimental therapeutics.
[28] Bryan L. Roth,et al. Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.
[29] R. Glennon,et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis , 1989, Psychopharmacology.
[30] G. Kennett,et al. Evidence that hypophagia induced bymCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors , 2006, Psychopharmacology.
[31] R. Porter,et al. Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.
[32] G. Martin,et al. 5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome , 1997, Neuropharmacology.
[33] M. Millan,et al. 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. , 1997, European journal of pharmacology.
[34] L. Parsons,et al. Enhanced Locomotor, Reinforcing, and Neurochemical Effects of Cocaine in Serotonin 5-Hydroxytryptamine 2C Receptor Mutant Mice , 2002, The Journal of Neuroscience.
[35] T. Blackburn,et al. BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.
[36] B. Roth. Drugs and valvular heart disease. , 2007, The New England journal of medicine.
[37] A. Brown,et al. SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.
[38] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[39] David Julius,et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.
[40] J. Ponder,et al. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.
[41] A. Sleight,et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.
[42] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[43] N. Weissman. Appetite suppressant valvulopathy : A review of current data , 1999 .
[44] R. Glennon,et al. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain. , 1990, The Journal of pharmacology and experimental therapeutics.
[45] J. Vry,et al. Effects of selected serotonin 5-HT1 and 5-HT2 receptor agonists on feeding behavior: possible mechanisms of action , 2000, Neuroscience & Biobehavioral Reviews.
[46] H Weinstein,et al. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus. , 1996, Molecular pharmacology.
[47] Ruben Abagyan,et al. Structure based prediction of subtype-selectivity for adenosine receptor antagonists , 2011, Neuropharmacology.
[48] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[49] J. Baldwin,et al. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.
[50] K. Miller. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. , 2005, Molecular interventions.
[51] R. Glennon,et al. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens , 2004, Psychopharmacology.
[52] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[53] G. Aghajanian,et al. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. , 1996, The Journal of pharmacology and experimental therapeutics.
[54] R. Glennon,et al. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors , 1998, Psychopharmacology.
[55] B. Roth,et al. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. , 2000, Molecular pharmacology.
[56] B. Roth,et al. Insights into the structure and function of 5-HT2 familyserotonin receptors reveal novel strategies for therapeutic target development , 2001, Expert opinion on therapeutic targets.
[57] Philippe Manivet,et al. The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. , 2002, The Journal of biological chemistry.
[58] F E Cohen,et al. Novel method for the rapid evaluation of packing in protein structures. , 1990, Journal of molecular biology.
[59] A. Sleight,et al. Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. , 1997, Journal of medicinal chemistry.
[60] R. Abagyan,et al. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.
[61] Philippe Manivet,et al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. , 2003, Life sciences.
[62] D. Baker,et al. Clustering of low-energy conformations near the native structures of small proteins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.